Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on November 7, 2016. The registrant is a Delaware corporation headquartered in San Diego, California, focused on oncology diagnostics.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
On November 7, 2016, the U.S. Patent and Trademark Office issued Patent No. 9,453,265 to the Company. The patent is entitled "Method for Detection of High Risk Human Papillomavirus."
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard disclosure of the patent issuance. The event is categorized under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the exact scope and claims of U.S. Patent No. 9,453,265 regarding high-risk HPV detection.
- Confirm the commercialization strategy for the patented method.
- Review the full text of the press release furnished as Exhibit 99.1 for additional details.
- Note the discrepancy between the requested company name (Cardiff Oncology) and the filing registrant (Trovagene).